Press Releases

Oct 16, 2019, 07:00 ET CRANBURY, N.J., Oct. 16, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) announced today that data from two pivotal, double-blind placebo-controlled Phase 3 trials (RECONNECT) and the Exit Survey/Interview data on Vyleesi™ (bremelanotide injection) for hypoactive sexual desire disorder (HSDD) will be presented at the 13th European Society of […]

Teleconference and Webcast to be held on September 12, 2019 Sep 12, 2019, 07:30 ET CRANBURY, N.J., Sept. 12, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose product candidates are targeted, receptor-specific

Sep 11, 2019, 12:00 ET CRANBURY, N.J., Sept. 11, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2019 operating results on Thursday, September 12, 2019 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by

Aug 06, 2019, 07:00 ET CRANBURY, N.J., Aug. 6, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) announced today that it will be presenting at Canaccord Genuity’s 39th Annual Growth Conference on Wednesday, August 7, 2019, at 10:30 am ET.  The conference will be held at the InterContinental Hotel in Boston, MA. Carl Spana,

– Vyleesi™ Approved by FDA for Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) – Approximately $102 Million in Pro Forma Cash and Equivalents at June 30, 2019 CRANBURY, N.J., July 1, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with

First FDA-Approved As-Needed Treatment for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women NDA Approval Triggers $60 Million Milestone Payment to Palatin Jun 21, 2019, 17:40 ET CRANBURY, N.J., June 21, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval

PL-8177 is a Melanocortin Receptor 1 Agonist CRANBURY, N.J., June 6, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation

May 09, 2019, 07:30 ET CRANBURY, N.J., May 9, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2019.  Recent Highlights and Program Updates Female Sexual

May 03, 2019, 16:30 ET CRANBURY, N.J., May 3, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2019 operating results on Thursday, May 9, 2019 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its

Study Met All Primary and Secondary Endpoints PL-8177 is a Melanocortin Receptor 1 Agonist Apr 04, 2019, 07:30 ET CRANBURY, N.J., April 4, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced positive